Vitasora Raises $4 Million Placement Led by $3 Million Cornerstone Investment

Placement Surpasses Target with Major Cornerstone Backing

Vitasora Health Limited (ASX:VHL) has dramatically exceeded its capital raising goal, securing $4.0 million through a placement that was nearly three times oversubscribed against its initial $1.5 million target. This surge of investor demand was led by a $3.0 million cornerstone commitment from private investor Bob Peters, who is set to become a substantial shareholder. The board welcomed Peters’ investment as a strong endorsement of Vitasora’s strategy, US leadership, and its vCare Electronic Medical Records (EMR) platform.

Directors Align Interests with Shareholders

In a move to further align management with shareholder interests, Vitasora’s directors intend to subscribe for up to $250,000 worth of new shares on the same terms as the placement. This participation remains subject to shareholder approval, which will be sought at an upcoming general meeting. The new shares issued under the placement were priced at $0.01 each, representing an 11% discount to the 15-day volume weighted average price (VWAP), and were issued within existing placement capacity, avoiding the need for immediate shareholder approval.

Rapid Acceleration in Monthly Billings

Vitasora’s capital raise comes amid a period of accelerating commercial momentum. Average daily billings across its Ceras and vCare programs have climbed sharply, rising from US$7,321 in April 2026 to US$9,500 in May (a 30% increase), and further to US$12,412 in June month-to-date, marking a 70% increase since April. The most recent five billing days averaged US$13,262 daily, nearly doubling April’s figures. These metrics reflect strong uptake of Vitasora’s remote patient monitoring and chronic care management solutions, powered by its AI-driven vCare platform.

Funding Growth and Path to Cashflow Breakeven

The funds raised will primarily support patient and account management, sales and marketing expansion, ongoing enhancements and rollout of the vCare platform, and general working capital. CEO Marjan Mikel highlighted that the capital injection validates Vitasora’s execution and strategy, positioning the company to reach monthly cashflow breakeven in the second half of 2026. This milestone is critical as the company scales its US operations and commercial footprint.

Investor Confidence and Next Steps

Non-Executive Chairman Nicholas Smedley emphasised that the board’s intention to invest alongside a high-calibre private investor sends a clear signal of confidence in Vitasora’s growth trajectory. With a strengthened balance sheet, the company is poised to focus on disciplined delivery of its expansion plans. Investors will be watching closely for the outcome of the forthcoming shareholder meeting on director participation and subsequent monthly billing trends as indicators of sustained momentum.